Survival Pattern Depending on Hormone Receptor Status, Stages of Breast Cancer and Social-Economic Status- A Cohort Study

Baisil, Sharon; Kundapur, Rashmi; Chandramoha, Sachin; Nelliyanil, Maria; Abhraham, Prince; Shetty, Vijith; Ballal, Rajesh

doi:10.30699/jogcr.7.3.221

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of progesterone receptors is regulated by the hormone estrogen, so most tumors that are positive progesterone receptors also express estrogen receptors, which usually appear after menopause, and increase with age of tumors with estrogen receptors; while estrogen receptors are less protective in pre-menopausal patients, ER-positive tumors are less common in younger women, and may be due to malignant breast cancer in the youngers (15). The pattern of receptor among patients in our study showed 52.69% ER, 50% PR positivity, which was in consistent with a study conducted by Sharon Baisil et al,(16).…”

Section: Discussionsupporting

confidence: 93%

Prevalence and Correlates of the Estrogen and Progesterone Receptors (ER/PR), Human Epidermal Growth Factor Receptor-2 (HER-2) and P53 in Breast Cancer: a Cross-Sectional Study

Akbari

Forouzandeh

Mirshekari

et al. 2022

J Obstet Gynecol Cancer Res

View full text Add to dashboard Cite

Background & Objective: Breast cancer has a pivotal role in many deaths caused by malignancies. Epidermal growth factor receptor-2 (EGFR-2 or HER-2) and estrogen receptor (ER) have immense predictive values as prognostic factors. Breast cancers that have steroid receptors and respond to hormone therapy show a better prognosis than cancers without steroid receptors. Materials & Methods:A retrospective cross-sectional study was performed on 500 pathology blocks of women with breast cancer sent to the pathology department of Amir-al-Momenin medical and educational center, Gerash, Iran, from 2016 to 2019. Data were analyzed by SPSS software (Version-16) via ANOVA test followed by Chisquare and t-tests. P-value <0.05 was considered as significant. Results:The utmost type of malignancy was invasive ductal carcinoma (IDC) at 35.03%. Among ER-positive patients 59.67% were HER-2-positive. Nonetheless, among the PR-positive patients 54.74% were HER-2-positive. ER-positive patients were correlated with p53 receptor, distant metastasis and HER-2 significantly (P<0.01). However, PR-positive patients just correlated with p53 receptor significantly (P<0.01). Conclusion:Investigated samples were more ER-negative and less PR-positive compared to similar studies. Meanwhile, ER-positive patients were HER-2-positive. Regarding the correlation with prognosis of breast cancer, especially in HER-2positive patients, there is a need to perform profound screening programs for HER-2 in breast cancer patients, especially with histopathological characteristics of invasive ductal carcinoma.

show abstract

Section: Discussionsupporting

confidence: 93%